{"id":"ciclosporine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"20.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":2280,"totalAffected":456,"trialsReporting":2},{"effect":"Oedema peripheral","drugRate":"29.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":407,"trialsReporting":2},{"effect":"Diarrhoea","drugRate":"23.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":321,"trialsReporting":2},{"effect":"Pyrexia","drugRate":"11.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":2626,"totalAffected":295,"trialsReporting":3},{"effect":"Urinary tract infection","drugRate":"21.6%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":1360,"totalAffected":294,"trialsReporting":2},{"effect":"Hypertension","drugRate":"20.2%","organSystem":"Vascular disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":275,"trialsReporting":2},{"effect":"Anaemia","drugRate":"19.7%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":268,"trialsReporting":2},{"effect":"Constipation","drugRate":"24.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":245,"trialsReporting":1},{"effect":"Nausea","drugRate":"15.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":212,"trialsReporting":2},{"effect":"Hypophosphataemia","drugRate":"18.7%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":190,"trialsReporting":1},{"effect":"Proteinuria","drugRate":"13.5%","organSystem":"Renal and urinary disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":183,"trialsReporting":2},{"effect":"Hypokalaemia","drugRate":"12.6%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":172,"trialsReporting":2},{"effect":"Blood creatinine increased","drugRate":"12.6%","organSystem":"Investigations","placeboRate":"","totalAtRisk":1360,"totalAffected":171,"trialsReporting":2},{"effect":"Hyperkalaemia","drugRate":"16.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":164,"trialsReporting":1},{"effect":"Hyperlipidaemia","drugRate":"11.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":152,"trialsReporting":2},{"effect":"Diabetes mellitus","drugRate":"10.9%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":148,"trialsReporting":2},{"effect":"Hypercholesterolaemia","drugRate":"10.5%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":143,"trialsReporting":2},{"effect":"Leukopenia","drugRate":"10.4%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":142,"trialsReporting":2},{"effect":"Vomiting","drugRate":"10.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":141,"trialsReporting":2},{"effect":"Nasopharyngitis","drugRate":"10.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":1360,"totalAffected":141,"trialsReporting":2},{"effect":"Hyperglycaemia","drugRate":"13.8%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":140,"trialsReporting":1},{"effect":"Hypomagnesaemia","drugRate":"13.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":134,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"5.9%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":2280,"totalAffected":134,"trialsReporting":2},{"effect":"Dyslipidaemia","drugRate":"9.1%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":124,"trialsReporting":2},{"effect":"Cough","drugRate":"8.5%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":115,"trialsReporting":2},{"effect":"Hypocalcaemia","drugRate":"10.7%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":109,"trialsReporting":1},{"effect":"Influenza Like Illness","drugRate":"8.5%","organSystem":"General disorders","placeboRate":"","totalAtRisk":1266,"totalAffected":108,"trialsReporting":1},{"effect":"Haematuria","drugRate":"10.1%","organSystem":"Renal and urinary disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":102,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"7.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":1360,"totalAffected":101,"trialsReporting":2},{"effect":"Tremor","drugRate":"9.9%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":100,"trialsReporting":1},{"effect":"Insomnia","drugRate":"9.9%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":100,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"9.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":94,"trialsReporting":1},{"effect":"Back pain","drugRate":"9.2%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":93,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"6.8%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":92,"trialsReporting":2},{"effect":"Procedural pain","drugRate":"8.9%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":1014,"totalAffected":90,"trialsReporting":1},{"effect":"Metabolic acidosis","drugRate":"7.6%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":77,"trialsReporting":1},{"effect":"Acne","drugRate":"5.5%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":1360,"totalAffected":75,"trialsReporting":2},{"effect":"Thrombocytopenia","drugRate":"7.3%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":74,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"6.5%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":66,"trialsReporting":1},{"effect":"Complications of transplanted kidney","drugRate":"6.2%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":1014,"totalAffected":63,"trialsReporting":1},{"effect":"Hypotension","drugRate":"6.1%","organSystem":"Vascular disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":62,"trialsReporting":1},{"effect":"BK virus infection","drugRate":"4.5%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":1360,"totalAffected":61,"trialsReporting":2},{"effect":"Dysuria","drugRate":"5.9%","organSystem":"Renal and urinary disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":60,"trialsReporting":1},{"effect":"Fatigue","drugRate":"5.8%","organSystem":"General disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":59,"trialsReporting":1},{"effect":"Hypertriglyceridaemia","drugRate":"5.7%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":58,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"5.2%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":53,"trialsReporting":1},{"effect":"Vitamin D deficiency","drugRate":"5.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":53,"trialsReporting":1},{"effect":"Polycythaemia","drugRate":"5.1%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":52,"trialsReporting":1},{"effect":"Incision site pain","drugRate":"5.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":1014,"totalAffected":51,"trialsReporting":1},{"effect":"Dizziness","drugRate":"5.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":1014,"totalAffected":51,"trialsReporting":1}],"contraindications":["BK Polyomavirus Reactivation Nephropathy","Benign intracranial hypertension","Breastfeeding (mother)","Cyclosporine Toxicity","Disease of liver","Disorder of brain","Eye infection","Hyperbilirubinemia","Hypercholesterolemia","Hyperkalemia","Hypertensive disorder","Hypertensive urgency","Hypertriglyceridemia","Hyperuricemia","Hypomagnesemia","Infectious disease","Kidney disease","Liver function tests abnormal","Malignant lymphoma","Metabolic acidosis, normal anion gap, acidifying salts","Neoplasm","Primary malignant neoplasm","Seizure disorder","Thrombotic thrombocytopenic purpura","Toxic nephropathy"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"event":"Urinary tract infection","detail":"Infections and infestations. 2 trial(s).","severity":"serious","incidence":"7.6%"},{"event":"Pneumonia","detail":"Infections and infestations. 2 trial(s).","severity":"serious","incidence":"5.1%"},{"event":"Transplant rejection","detail":"Immune system disorders. 2 trial(s).","severity":"serious","incidence":"5.0%"},{"event":"Blood creatinine increased","detail":"Investigations. 2 trial(s).","severity":"serious","incidence":"4.9%"},{"event":"Acute kidney injury","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"4.5%"},{"event":"Diarrhoea","detail":"Gastrointestinal disorders. 2 trial(s).","severity":"serious","incidence":"3.1%"},{"event":"Complications of transplanted kidney","detail":"Injury, poisoning and procedural complications. 2 trial(s).","severity":"serious","incidence":"2.9%"},{"event":"Kidney transplant rejection","detail":"Immune system disorders. 2 trial(s).","severity":"serious","incidence":"2.7%"},{"event":"Pyelonephritis","detail":"Infections and infestations. 2 trial(s).","severity":"serious","incidence":"2.7%"},{"event":"Lymphocele","detail":"Vascular disorders. 2 trial(s).","severity":"serious","incidence":"2.6%"},{"event":"Pyrexia","detail":"General disorders. 3 trial(s).","severity":"serious","incidence":"2.4%"},{"event":"Urosepsis","detail":"Infections and infestations. 2 trial(s).","severity":"serious","incidence":"2.4%"},{"event":"Gastroenteritis","detail":"Infections and infestations. 2 trial(s).","severity":"serious","incidence":"2.1%"},{"event":"Renal impairment","detail":"Renal and urinary disorders. 2 trial(s).","severity":"serious","incidence":"2.1%"},{"event":"Renal failure acute","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"2.0%"},{"event":"Sepsis","detail":"Infections and infestations. 2 trial(s).","severity":"serious","incidence":"1.9%"},{"event":"Deep vein thrombosis","detail":"Vascular disorders. 2 trial(s).","severity":"serious","incidence":"1.9%"},{"event":"Proteinuria","detail":"Renal and urinary disorders. 2 trial(s).","severity":"serious","incidence":"1.7%"},{"event":"Pulmonary embolism","detail":"Respiratory, thoracic and mediastinal disorders. 2 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Graft loss","detail":"Injury, poisoning and procedural complications. 2 trial(s).","severity":"serious","incidence":"1.3%"},{"event":"Anaemia","detail":"Blood and lymphatic system disorders. 2 trial(s).","severity":"serious","incidence":"1.1%"},{"event":"Atrial fibrillation","detail":"Cardiac disorders. 2 trial(s).","severity":"serious","incidence":"1.1%"},{"event":"Hyperkalaemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"1.1%"},{"event":"Psoriasis","detail":"Skin and subcutaneous tissue disorders. 1 trial(s).","severity":"serious","incidence":"1.1%"},{"event":"Cardiac failure","detail":"Cardiac disorders. 2 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Wound dehiscence","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Haematuria","detail":"Renal and urinary disorders. 2 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Osteonecrosis","detail":"Musculoskeletal and connective tissue disorders. 2 trial(s).","severity":"serious","incidence":"0.9%"},{"event":"Hydronephrosis","detail":"Renal and urinary disorders. 2 trial(s).","severity":"serious","incidence":"0.9%"},{"event":"Urinary incontinence","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.9%"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL160","moleculeType":"Protein","molecularWeight":"1202.63"},"aliases":[],"patents":[],"pricing":[],"_sources":{"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (4 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T10:55:46.840894+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2"},"_scrapedAt":"2026-03-28T00:44:56.503Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T10:55:54.120468+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Kawasaki's disease","diseaseId":"kawasaki's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Keratoconjunctivitis sicca","diseaseId":"keratoconjunctivitis-sicca","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Cardiac Transplant Rejection","diseaseId":"prevention-of-cardiac-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Kidney Transplant Rejection","diseaseId":"prevention-of-kidney-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Liver Transplant Rejection","diseaseId":"prevention-of-liver-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Severe Recalcitrant Psoriasis","diseaseId":"severe-recalcitrant-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tear film insufficiency","diseaseId":"tear-film-insufficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01659606","phase":"PHASE2","title":"Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2012-07","conditions":"Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome","enrollment":40},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT00977977","phase":"PHASE2","title":"Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2010-12-22","conditions":"Nephrotic Syndrome, Proteinuria, Autoimmune Disease","enrollment":30},{"nctId":"NCT07488728","phase":"NA","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2025-10-01","conditions":"EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir","enrollment":80},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT07290803","phase":"","title":"This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-17","conditions":"Atopic Dermatitis","enrollment":1000},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT01962636","phase":"NA","title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-12","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia","enrollment":200},{"nctId":"NCT07463950","phase":"PHASE4","title":"A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-20","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT04304820","phase":"PHASE2","title":"Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-05-07","conditions":"Severe Aplastic Anemia","enrollment":80},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT05692739","phase":"PHASE4","title":"Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye","status":"COMPLETED","sponsor":"Barbara Burgos Blasco","startDate":"2022-10-19","conditions":"Dry Eye, Insulin","enrollment":116},{"nctId":"NCT07449286","phase":"PHASE2","title":"IFN-α in Relapse Prevention.","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":100},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT04195633","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-25","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT07440654","phase":"NA","title":"Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-03-01","conditions":"aGVHD Prophylaxis","enrollment":40},{"nctId":"NCT04380740","phase":"PHASE2","title":"Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2022-03-30","conditions":"Graft Vs Host Disease","enrollment":160},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT02203396","phase":"PHASE2","title":"A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2014-08","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT05149365","phase":"PHASE3","title":"Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-12-22","conditions":"Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":190},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT07397936","phase":"PHASE4","title":"Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2024-08-01","conditions":"Dry Eye Disease (DED), Cataract","enrollment":55},{"nctId":"NCT04877288","phase":"PHASE3","title":"A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-21","conditions":"Renal Allograft Recipients","enrollment":102},{"nctId":"NCT07381556","phase":"PHASE4","title":"Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-11-01","conditions":"Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis","enrollment":50},{"nctId":"NCT06837259","phase":"PHASE1","title":"A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-03-19","conditions":"Healthy Adults","enrollment":26},{"nctId":"NCT07375654","phase":"PHASE1","title":"Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-12-19","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT07377058","phase":"NA","title":"RCT of Tocilizumab for Anti-MDA5+DM","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-11-01","conditions":"Dermatomyositis","enrollment":110},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT04180059","phase":"PHASE1","title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-09","conditions":"Haematologic Disease","enrollment":6},{"nctId":"NCT06790095","phase":"PHASE2","title":"TRACK-TBI Precision Medicine Part 3 - Option II","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Traumatic Brain Injury","enrollment":26},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT07368595","phase":"PHASE4","title":"Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT06013423","phase":"PHASE2","title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-07-23","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT05166967","phase":"PHASE3","title":"Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-01-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":204},{"nctId":"NCT06812598","phase":"NA","title":"Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-16","conditions":"Cytomegalovirus Infections, CMV","enrollment":330},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT03585946","phase":"","title":"Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2030-01-01","conditions":"Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction","enrollment":""},{"nctId":"NCT07336641","phase":"","title":"LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice","status":"NOT_YET_RECRUITING","sponsor":"Fondazione ISIDE","startDate":"2026-01","conditions":"Psoriasis, Atopic Dermatitis, Vitiligo","enrollment":20000},{"nctId":"NCT07345000","phase":"PHASE3","title":"A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Treatment-naïve Severe Aplastic Anemia","enrollment":210},{"nctId":"NCT04328727","phase":"PHASE2","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-04","conditions":"Severe Aplastic Anemia (SAA)","enrollment":36},{"nctId":"NCT07338422","phase":"NA","title":"HID-HSCT Versus IST as First-line Treatment for SAA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-14","conditions":"Aplastic Anaemia","enrollment":116},{"nctId":"NCT06136767","phase":"","title":"Registry for Systemic Eczema Treatments","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-01-17","conditions":"Atopic Dermatitis","enrollment":400},{"nctId":"NCT07319793","phase":"NA","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","enrollment":200},{"nctId":"NCT06334497","phase":"PHASE3","title":"Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-08-14","conditions":"Cytomegalovirus Infection","enrollment":80},{"nctId":"NCT00133887","phase":"PHASE3","title":"TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-04","conditions":"Skin Cancer, Kidney Transplantation","enrollment":77},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT07297550","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-15","conditions":"Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia","enrollment":42},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT07102849","phase":"","title":"Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study","status":"ENROLLING_BY_INVITATION","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2025-09-09","conditions":"Bone Marrow Failure Disorders, VEXAS Syndrome, Hemoglobinurea, Paroxysmal","enrollment":1400},{"nctId":"NCT00799188","phase":"PHASE3","title":"CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-10","conditions":"Cardiac Transplantation, Skin Cancer","enrollment":175},{"nctId":"NCT03128034","phase":"PHASE1, PHASE2","title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-10-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT06430788","phase":"PHASE2","title":"A Study of Emapalumab for Pediatric Aplastic Anemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-05-21","conditions":"Aplastic Anemia, Cytopenia, Hypocellular Marrow","enrollment":35},{"nctId":"NCT01743131","phase":"PHASE2","title":"Abatacept as GVHD Prophylaxis Phase 2","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-02-01","conditions":"Graft vs Host Disease, Malignancy","enrollment":186},{"nctId":"NCT04743739","phase":"PHASE3","title":"Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN","status":"TERMINATED","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":12},{"nctId":"NCT07267299","phase":"PHASE4","title":"Switching From Restasis to TRYPTYR","status":"NOT_YET_RECRUITING","sponsor":"Southern College of Optometry","startDate":"2025-12-01","conditions":"Dry Eye, Eye Diseases, Chronic Dry Eye","enrollment":100},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT04795752","phase":"NA","title":"Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)","status":"COMPLETED","sponsor":"Sight Sciences, Inc.","startDate":"2021-04-28","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":345},{"nctId":"NCT06642909","phase":"PHASE2","title":"A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2024-11-13","conditions":"Primary Membranous Nephropathy","enrollment":135},{"nctId":"NCT07239128","phase":"EARLY_PHASE1","title":"Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus","status":"COMPLETED","sponsor":"University of Seville","startDate":"2024-05-01","conditions":"Dry Eye Disease (DED)","enrollment":160},{"nctId":"NCT06981104","phase":"NA","title":"Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-18","conditions":"Dry Eye Disease (DED), Asthenopia","enrollment":60},{"nctId":"NCT07234318","phase":"","title":"Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2025-12-15","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT05398653","phase":"PHASE1, PHASE2","title":"A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"COMPLETED","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2022-02-24","conditions":"Primary Membranous Nephropathy","enrollment":94},{"nctId":"NCT02143830","phase":"PHASE2","title":"HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-04","conditions":"Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS)","enrollment":70},{"nctId":"NCT07025811","phase":"PHASE4","title":"A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-09","conditions":"Dry Eye Disease","enrollment":350},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":"Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":140},{"nctId":"NCT06658002","phase":"PHASE3","title":"Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-01","conditions":"Fungal Keratitis, Corneal Ulcer","enrollment":150},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT03216967","phase":"PHASE4","title":"Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2018-01-15","conditions":"BK Virus Nephropathy After Kidney Transplantation","enrollment":130},{"nctId":"NCT07173114","phase":"","title":"New Approaches for Evaluating the Interchangeability of Reference Materials and Quality Controls (COMET-MPL)","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09-22","conditions":"Hospitalization, All Conditions","enrollment":300},{"nctId":"NCT07196449","phase":"PHASE1","title":"Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2025-05-14","conditions":"Drug Drug Interaction (DDI)","enrollment":12},{"nctId":"NCT00809172","phase":"PHASE3","title":"Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-12","conditions":"Atopic Dermatitis","enrollment":100},{"nctId":"NCT06903884","phase":"PHASE3","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-12-30","conditions":"Vernal Keratoconjunctivitis","enrollment":94},{"nctId":"NCT05399732","phase":"PHASE2","title":"Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia","status":"COMPLETED","sponsor":"Bing Han","startDate":"2022-12-19","conditions":"Aplastic Anemia","enrollment":58},{"nctId":"NCT06488651","phase":"","title":"Trajectory of Immunosuppression-Caused Tremor In Kidney and Lung Transplant Recipients","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-08-17","conditions":"Kidney Transplantation, Tremor","enrollment":72},{"nctId":"NCT07171710","phase":"NA","title":"Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Eye Hospital","startDate":"2024-03-01","conditions":"Dry Eye Disease","enrollment":30},{"nctId":"NCT07169695","phase":"PHASE2","title":"A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2026-03-02","conditions":"Moderate to Severe Vernal Keratoconjunctivitis","enrollment":120},{"nctId":"NCT07029204","phase":"EARLY_PHASE1","title":"Intralesional Cyclosporine for Alopecia Areata","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-08-19","conditions":"Alopecia Areata","enrollment":12},{"nctId":"NCT06892756","phase":"PHASE1","title":"Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-03-18","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT07089511","phase":"NA","title":"Cord Blood Platelet Poor Plasma Eye Drops","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2025-03-11","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT05884333","phase":"PHASE2","title":"Cord Blood Transplant in Adults With Blood Cancers","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-22","conditions":"Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)","enrollment":54},{"nctId":"NCT01502774","phase":"PHASE3","title":"Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-04","conditions":"ST Elevation Acute Myocardial Infarction","enrollment":970},{"nctId":"NCT06936462","phase":"NA","title":"Potential Role of Ocular Surface Microbiome in Dry Eye: Microbial Interactions and Symptom Alleviation","status":"COMPLETED","sponsor":"Hallym University Kangnam Sacred Heart Hospital","startDate":"2020-01-20","conditions":"Dry Eye Syndrome (DES)","enrollment":50},{"nctId":"NCT01595958","phase":"PHASE3","title":"Cyclosporine A in Cardiac Arrest","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2010-06","conditions":"Non Shockable Out of Hospital Cardiac Arrest","enrollment":796},{"nctId":"NCT06329661","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2024-04-22","conditions":"Dry Eye Disease","enrollment":204},{"nctId":"NCT01282073","phase":"PHASE3","title":"Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2011-03","conditions":"Glomerulonephritis, Membranous","enrollment":43},{"nctId":"NCT00357565","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-11","conditions":"Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission","enrollment":34},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT05862233","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2023-06-02","conditions":"Primary Membranous Nephropathy","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":38,"reaction":"DRUG INEFFECTIVE"},{"count":37,"reaction":"OFF LABEL USE"},{"count":18,"reaction":"ACUTE GRAFT VERSUS HOST DISEASE"},{"count":17,"reaction":"PYREXIA"},{"count":16,"reaction":"CONDITION AGGRAVATED"},{"count":15,"reaction":"DRUG INTERACTION"},{"count":14,"reaction":"ACUTE KIDNEY INJURY"},{"count":13,"reaction":"CHRONIC GRAFT VERSUS HOST DISEASE"},{"count":13,"reaction":"NEUTROPENIA"},{"count":12,"reaction":"SEPTIC SHOCK"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":166,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"structuredTrialResults":[{"hr":"3.0","nctId":"NCT01950819","phase":"PHASE4","pValue":"0.001","ciLower":"-1.4","ciUpper":"7.3","endpoint":"Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2.","enrollment":2037}],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"ciclosporine","genericName":"ciclosporine","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciclosporine is an immunosuppressant medication used to prevent organ rejection in transplant patients, including those receiving kidney, lung, and liver transplants. It works by modulating cyclophilin A, a protein involved in the immune response, and is typically taken orally or intravenously.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":8,"withResults":4},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T10:55:54.120468+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}